Urodynamix, Pfizer educate clinicians on spectroscopy device for enlarged prostrate, LUTS diagnosis
SEPTEMBER 25, 2008 -- Urodynamix Technologies Ltd. (Vancouver, BC, Canada) has entered into an agreement with pharmaceuticals giant Pfizer Inc. to collaborate on a series of promotional programs to increase awareness of UroNIRS Bladder Monitor technology among urologists and medical professionals.
The program will be delivered to medical professionals in cities across the United States starting in November; it will feature Urodynamix's non-invasive UroNIRS medical device that uses near infrared spectroscopy (NiRS) for diagnosis of lower urinary tract symptoms (LUTS), a major health concern related to benign prostrate hyperplasia (BPH) and prostate disease. Experts will discuss the current and future applications of UroNIRS technology for the diagnosis of urologic conditions including LUTS, BPH and erectile dysfunction (ED). The program will be coordinated through Pfizer's urology sales force.
In May, Urodynamix and Laborie Medical Technologies (Montreal, Que, Canada), a global provider of urodynamics equipment and related products, announced the U.S. launch of the Tetra Bladder Monitor System, a NIRS-based device that aids in the diagnosis of LUTS. In 2007, Laborie began distributing UroNIRS device in acute care settings through its network of direct sales representatives and distributors in 52 countries across North America, South America, Europe, Asia and Oceania.
More information:
Urodynamix's NIRS technology
Pfizer